Bright Minds Biosciences (BMBIF) announced a presentation at the H.C. Wainwright 23rd Annual Global Investment Conference scheduled for September 13, 2021. CEO Ian McDonald and CSO Dr. Alan Kozikowski will present virtually, available on demand from 7:00 AM ET. Additionally, the company revealed that its shares are now DTC eligible, facilitating faster electronic clearing and settlement in the U.S. market. This advancement is expected to improve liquidity and simplify trading for investors in BMBIF, which focuses on innovative treatments for neuropsychiatric disorders and epilepsy.
Bright Minds Biosciences (BMB) announced promising pre-clinical findings for its proprietary 5-HT2C agonist, BMB-101, which shows effectiveness in reducing seizure duration and frequency in rodent models of Dravet Syndrome and Epilepsy. The results are consistent with existing anti-epileptic drugs like fenfluramine, indicating a potential breakthrough in treating difficult-to-manage epileptic conditions. The Scn1Lab zebrafish model and two rodent studies demonstrated BMB-101's capability in significantly lowering seizure activity.
Bright Minds Biosciences (BMBIF) has applied to list on The Nasdaq Stock Market, reserving the symbol 'DRUG'. CEO Ian McDonald emphasizes the move aligns with the rise of serotonergic therapeutics and the company’s innovative drug pipeline aimed at neuropsychiatry disorders and epilepsy. A Registration Statement has been filed with the SEC, and the listing is subject to regulatory approval. Additionally, BMB has granted 180,000 stock options, exercisable at $7.60 per share over five years. The company focuses on developing next-generation serotonin agonists to improve treatment options.
Bright Minds Biosciences announced key appointments to enhance its drug development efforts. Dr. Emer Leahy joins the Board of Directors, bringing over 30 years of experience in pharmaceutical business development. Dr. Tom Lategan, as Vice President of Regulatory Affairs, adds over 20 years of regulatory expertise. The Company aims to advance transformative treatments for neuropsychiatry disorders and epilepsy, focusing on next-generation serotonin agonists. These additions are positioned to enhance Bright Minds’ capacity to deliver targeted therapeutics amidst a competitive landscape.
Bright Minds Biosciences, a biotechnology firm focused on innovative treatments for neuropsychiatry disorders, epilepsy, and pain, announced participation in the H.C. Wainwright Virtual Conference on June 17, 2021. CEO Ian McDonald and VP of Discovery Dr. Gideon Shapiro will present on-demand starting at 7:00 AM ET. The conference aims to showcase advancements in psychedelic therapies. Bright Minds specializes in next-generation serotonin agonists aimed at enhancing treatment outcomes while reducing side effects compared to traditional compounds.
Bright Minds Biosciences (BMBIF), a biotechnology company, announced its participation in the 2021 LD Micro Invitational XI, where Ian McDonald, CEO, and Dr. Gideon Shapiro, VP of Discovery, will present on June 10, 2021, at 12:30 PM ET. The presentation will focus on developing new treatments for neuropsychiatry disorders, epilepsy, and pain, utilizing next-generation serotonin agonists. The event will be broadcast live, with a replay available for seven days. Bright Minds aims to deliver effective therapies that enhance the therapeutic aspects of serotonergic compounds while minimizing side effects.
Bright Minds Biosciences (BMBIF) announced its shares began trading on the OTCQB Venture Market on May 17, 2021. This move supports the company's growth strategy, enhancing visibility and liquidity for its transformative treatments targeting neuropsychiatry disorders and pain. The OTCQB market is designed for developing companies, ensuring rigorous compliance and financial standards. Additionally, BMBIF has entered a debt settlement agreement to issue 6,100 common shares for CAD$36,600 in debt, facilitating improved capital structure.